Baseline Hb levels, baseline LHD%>5.5, disease activity and clinical response to treatment also remained as a significant factor for the increase of Hb, suggesting that not only TCZ use but also baseline anemic state, functional iron deficiency, and the state of inflammation collectively determine the change of Hb levels after biologic therapies (Table 3). Here, GSTM1 is linked to nutritional disorder.